PFECL.SN
PFIZER INC News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 7,
"returned": 6,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "31f24948-dc85-4ff3-9ec0-645669cfd69a",
"title": "Global Oral Transmucosal Drugs Market Size To Exceed USD 62.3 Billion By 2033 | CAGR Of 6.5%",
"description": "The Global Oral Transmucosal Drugs Market Size was Valued at USD 33.2 Billion in 2023 and the Worldwide Oral Transmucosal Drugs Market Size is Expected to...",
"keywords": "SPHERICAL INSIGHTS LLP, Oral Transmucosal Drugs Market, Transmucosal Drugs Market Size, Oral Transmucosal Market Share, Market Growth, Analysis, Trends, Si",
"snippet": "New York, United States , May 16, 2024 (GLOBE NEWSWIRE) -- The Global Oral Transmucosal Drugs Market Size is to Grow from USD 33.2 Billion in 2023 to USD 62.3 B...",
"url": "https://www.globenewswire.com/news-release/2024/05/16/2883828/0/en/Global-Oral-Transmucosal-Drugs-Market-Size-To-Exceed-USD-62-3-Billion-By-2033-CAGR-Of-6-5.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/b27a94e8-407e-46ae-a5c2-47bb2a1c8a2e",
"language": "en",
"published_at": "2024-05-16T19:00:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "PFECL.SN",
"name": "PFIZER INC",
"exchange": null,
"exchange_long": null,
"country": "cl",
"type": "equity",
"industry": "N/A",
"match_score": 8.499471,
"sentiment_score": -0.2263,
"highlights": [
{
"highlight": "Ltd, IntelGenx Corp, CURE Pharmaceutical, Seoul Pharmaceuticals, Aquestive Therapeutics, Inc, Jazz Pharmaceuticals, plc, NAL Pharma, Novartis AG, <em>Pfizer</em> <em>Inc</em>, Teva Pharmaceutical Industries Limited, and Others\n\nGet Discount At @ https://www.sphericalinsights.com/request-discount/4011\n\nMarket Segment\n\nThis study forecasts revenue at global, regional,",
"sentiment": -0.2263,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "4418c5e7-7dab-4b90-8e69-7b100ddba226",
"title": "Vepdegestrant si dimostra promettente nello studio sul cancro al seno Da Investing.com",
"description": "Vepdegestrant si dimostra promettente nello studio sul cancro al seno",
"keywords": "",
"snippet": "NEW HAVEN, Conn. - Arvinas, Inc. (NASDAQ: ARVN) e Pfizer Inc. (NYSE: PFE) hanno annunciato oggi il proseguimento dei risultati positivi di uno studio di Fase 1b...",
"url": "https://it.investing.com/news/company-news/vepdegestrant-si-dimostra-promettente-nello-studio-sul-cancro-al-seno-93CH-2372079",
"image_url": "https://i-invdn-com.investing.com/news/World_News_8_800x533_L_1420026210.jpg",
"language": "it",
"published_at": "2024-05-16T10:20:59.000000Z",
"source": "it.investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "PFECL.SN",
"name": "PFIZER INC",
"exchange": null,
"exchange_long": null,
"country": "cl",
"type": "equity",
"industry": "N/A",
"match_score": 18.294731,
"sentiment_score": null,
"highlights": [
{
"highlight": "(NASDAQ: ARVN) e <em>Pfizer</em> <em>Inc</em>. (NYSE: PFE) hanno annunciato oggi il proseguimento dei risultati positivi di uno studio di Fase 1b su vepdegestrant in combinazione con palbociclib per il trattamento del carcinoma mammario avanzato ER+/HER2-.",
"sentiment": -0.0516,
"highlighted_in": "main_text"
},
{
"highlight": "Vepdegestrant è un degradatore orale PROTAC del recettore degli estrogeni in fase di sperimentazione, sviluppato congiuntamente da Arvinas e <em>Pfizer</em>. Il suo scopo è quello di sfruttare il sistema naturale di smaltimento delle proteine dell'organismo per degradare il recettore degli estrogeni, un bersaglio chiave nel cancro al seno ER+/HER2-.",
"sentiment": -0.0516,
"highlighted_in": "main_text"
},
{
"highlight": "Il Chief Development Officer, Oncology di <em>Pfizer</em> ha espresso la speranza di creare una nuova terapia endocrina standard per le pazienti con carcinoma mammario ER+/HER2-.",
"sentiment": -0.0516,
"highlighted_in": "main_text"
},
{
"highlight": "La collaborazione tra Arvinas e <em>Pfizer</em> prevede la condivisione dei costi di sviluppo, delle spese di commercializzazione e dei profitti a livello mondiale.\n\nQuesto articolo si basa su un comunicato stampa di Arvinas, Inc.\n\nApprofondimenti di InvestingPro\n\nMentre Arvinas, Inc.",
"sentiment": -0.0516,
"highlighted_in": "main_text"
},
{
"highlight": "L'impegno dell'azienda per l'innovazione nel trattamento del cancro al seno si riflette nella partnership strategica con <em>Pfizer</em> e nel potenziale del vepdegestrant come terapia rivoluzionaria.",
"sentiment": -0.0516,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "fde716fe-7ae1-457c-ac5a-4bd4570813fb",
"title": "Vepdegestrant shows promise in breast cancer trial By Investing.com",
"description": "Vepdegestrant shows promise in breast cancer trial",
"keywords": "",
"snippet": "NEW HAVEN, Conn. - Arvinas, Inc. (NASDAQ: ARVN) and Pfizer Inc. (NYSE: NYSE: ) today announced continued positive results from a Phase 1b trial of vepdegestrant...",
"url": "https://www.investing.com/news/company-news/vepdegestrant-shows-promise-in-breast-cancer-trial-93CH-3443567",
"image_url": "https://i-invdn-com.investing.com/news/news_pile_69x52._800x533_L_1419494209.jpg",
"language": "en",
"published_at": "2024-05-16T10:20:44.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "PFECL.SN",
"name": "PFIZER INC",
"exchange": null,
"exchange_long": null,
"country": "cl",
"type": "equity",
"industry": "N/A",
"match_score": 18.789925,
"sentiment_score": -0.04575,
"highlights": [
{
"highlight": "(NASDAQ: ARVN) and <em>Pfizer</em> <em>Inc</em>. (NYSE: NYSE: ) today announced continued positive results from a Phase 1b trial of vepdegestrant in combination with palbociclib for treating advanced ER+/HER2- breast cancer.",
"sentiment": 0.0516,
"highlighted_in": "main_text"
},
{
"highlight": "Vepdegestrant is an investigational oral PROTAC estrogen receptor degrader, being co-developed by Arvinas and <em>Pfizer</em>. It aims to leverage the body's natural protein disposal system to degrade the estrogen receptor, a key target in ER+/HER2- breast cancer.",
"sentiment": -0.8316,
"highlighted_in": "main_text"
},
{
"highlight": "The collaboration between Arvinas and <em>Pfizer</em> includes shared development costs, commercialization expenses, and profits worldwide.\n\nThis article is based on a press release statement from Arvinas, Inc.\n\nInvestingPro Insights\n\nAs Arvinas, Inc.",
"sentiment": 0.6486,
"highlighted_in": "main_text"
},
{
"highlight": "The company's commitment to innovation in breast cancer treatment is reflected in its strategic partnership with <em>Pfizer</em> and the potential of vepdegestrant as a game-changing therapy.",
"sentiment": -0.0516,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "0204c660-566c-428c-9692-98624f2d391a",
"title": "Autoimmune reaction identified in rare vaccine-linked blood clots",
"description": "Rare and fatal blood clots linked to COVID-19 vaccines stem from an autoimmune reaction in genetically predisposed individuals.",
"keywords": "",
"snippet": "Rare and fatal blood clots linked to Johnson & Johnson and AstraZeneca’s COVID-19 vaccines stem from an autoimmune reaction in genetically predisposed individ...",
"url": "https://www.biznews.com/health/2024/05/16/rare-vaccine-linked-blood-clots",
"image_url": "https://www.biznews.com/wp-content/uploads/2024/05/Untitled-design-2024-05-16T104624.853.png",
"language": "en",
"published_at": "2024-05-16T10:09:27.000000Z",
"source": "biznews.com",
"relevance_score": null,
"entities": [
{
"symbol": "PFECL.SN",
"name": "PFIZER INC",
"exchange": null,
"exchange_long": null,
"country": "cl",
"type": "equity",
"industry": "N/A",
"match_score": 14.963412,
"sentiment_score": 0.5209,
"highlights": [
{
"highlight": "The mRNA vaccines made by the <em>Pfizer</em> <em>Inc</em>.-BioNTech SE partnership and Moderna Inc. were later found to be more effective at protecting against Covid and have been updated to tackle more recent virus variants.\n\nRead also:\n\n© 2024 Bloomberg L.P.\n\nVisited 1 times, 1 visit(s) today",
"sentiment": 0.5209,
"highlighted_in": "main_text"
}
]
}
],
"similar": [
{
"uuid": "e4761be6-1b09-4f6c-8121-dc2627259fac",
"title": "Rare but deadly blood clots tied to Johnson & Johnson and AstraZeneca Covid-19 vaccines: scientists report to journal",
"description": "Adenovirus-based vaccines, like the J&J and AstraZeneca shots that were later pulled out from the market, contain a component that can trigger blood clots in genetically susceptible individuals, scientists reported Wednesday in a letter to the New England Journal of Medicine.",
"keywords": "Johnson & Johnson, AstraZeneca, Covid-19 vaccines, blood clots, autoimmune reaction, adenovirus-based vaccines, genetic susceptibility, Tom Gordon, Flinders University, thrombosis with thrombocytopenia syndrome, TTS, vaccine development, New England Journal of Medicine, Yale School of Medicine, vaccine withdrawal, AstraZeneca spokesperson, J&J research support, Pfizer-BioNTech, Moderna, mRNA vaccines, pandemic.",
"snippet": "Rare but deadly blood clots tied to Johnson & Johnson and AstraZeneca Plc’s Covid-19 vaccines were caused by an autoimmune reaction that some people are predi...",
"url": "https://www.livemint.com/news/world/rare-but-deadly-blood-clots-tied-to-johnson-johnson-and-astrazeneca-covid-19-vaccines-scientists-report-to-journal-11715842165667.html",
"image_url": "https://www.livemint.com/lm-img/img/2024/05/16/1600x900/2-0-74672285-STENT-3C--0_1681391056110_1715846898837.jpg",
"language": "en",
"published_at": "2024-05-16T08:26:36.000000Z",
"source": "livemint.com",
"relevance_score": null,
"entities": [
{
"symbol": "PFE.DE",
"name": "Pfizer Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 16.535776,
"sentiment_score": 0.7055,
"highlights": [
{
"highlight": "The mRNA vaccines made by the <em>Pfizer</em> <em>Inc</em>.-BioNTech SE partnership and Moderna Inc. were later found to be more effective at protecting against Covid and have been updated to tackle more recent virus variants.\n\n(With Inputs from Bloomberg)\n\nMilestone Alert!",
"sentiment": 0.7055,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "BNTXN.MX",
"name": "BioNTech SE",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "N/A",
"match_score": 18.107851,
"sentiment_score": 0.9144,
"highlights": [
{
"highlight": "-<em>BioNTech</em> <em>SE</em> partnership and Moderna Inc. were later found to be more effective at protecting against Covid and have been updated to tackle more recent virus variants.\n\n(With Inputs from Bloomberg)\n\nMilestone Alert! Livemint tops charts as the fastest growing news website in the world 🌏 Click here to know more.\n\nUnlock a world of Benefits!",
"sentiment": 0.9144,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MRNA.MX",
"name": "Moderna, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 15.489024,
"sentiment_score": 0.9144,
"highlights": [
{
"highlight": "-BioNTech SE partnership and <em>Moderna</em> <em>Inc</em>. were later found to be more effective at protecting against Covid and have been updated to tackle more recent virus variants.\n\n(With Inputs from Bloomberg)\n\nMilestone Alert! Livemint tops charts as the fastest growing news website in the world 🌏 Click here to know more.\n\nUnlock a world of Benefits!",
"sentiment": 0.9144,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "PFE.MX",
"name": "Pfizer Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 16.536251,
"sentiment_score": 0.7055,
"highlights": [
{
"highlight": "The mRNA vaccines made by the <em>Pfizer</em> <em>Inc</em>.-BioNTech SE partnership and Moderna Inc. were later found to be more effective at protecting against Covid and have been updated to tackle more recent virus variants.\n\n(With Inputs from Bloomberg)\n\nMilestone Alert!",
"sentiment": 0.7055,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "0A3M.L",
"name": "BioNTech SE",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 18.108131,
"sentiment_score": 0.9144,
"highlights": [
{
"highlight": "-<em>BioNTech</em> <em>SE</em> partnership and Moderna Inc. were later found to be more effective at protecting against Covid and have been updated to tackle more recent virus variants.\n\n(With Inputs from Bloomberg)\n\nMilestone Alert! Livemint tops charts as the fastest growing news website in the world 🌏 Click here to know more.\n\nUnlock a world of Benefits!",
"sentiment": 0.9144,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "0A45.L",
"name": "Moderna, Inc.",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 15.48921,
"sentiment_score": 0.9144,
"highlights": [
{
"highlight": "-BioNTech SE partnership and <em>Moderna</em> <em>Inc</em>. were later found to be more effective at protecting against Covid and have been updated to tackle more recent virus variants.\n\n(With Inputs from Bloomberg)\n\nMilestone Alert! Livemint tops charts as the fastest growing news website in the world 🌏 Click here to know more.\n\nUnlock a world of Benefits!",
"sentiment": 0.9144,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "BNTX",
"name": "BioNTech SE",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 18.108313,
"sentiment_score": 0.9144,
"highlights": [
{
"highlight": "-<em>BioNTech</em> <em>SE</em> partnership and Moderna Inc. were later found to be more effective at protecting against Covid and have been updated to tackle more recent virus variants.\n\n(With Inputs from Bloomberg)\n\nMilestone Alert! Livemint tops charts as the fastest growing news website in the world 🌏 Click here to know more.\n\nUnlock a world of Benefits!",
"sentiment": 0.9144,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "MRNA",
"name": "Moderna, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 15.489303,
"sentiment_score": 0.9144,
"highlights": [
{
"highlight": "-BioNTech SE partnership and <em>Moderna</em> <em>Inc</em>. were later found to be more effective at protecting against Covid and have been updated to tackle more recent virus variants.\n\n(With Inputs from Bloomberg)\n\nMilestone Alert! Livemint tops charts as the fastest growing news website in the world 🌏 Click here to know more.\n\nUnlock a world of Benefits!",
"sentiment": 0.9144,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "PFE",
"name": "Pfizer Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 16.536968,
"sentiment_score": 0.7055,
"highlights": [
{
"highlight": "The mRNA vaccines made by the <em>Pfizer</em> <em>Inc</em>.-BioNTech SE partnership and Moderna Inc. were later found to be more effective at protecting against Covid and have been updated to tackle more recent virus variants.\n\n(With Inputs from Bloomberg)\n\nMilestone Alert!",
"sentiment": 0.7055,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "PFE-WI",
"name": "Pfizer, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 16.536968,
"sentiment_score": 0.7055,
"highlights": [
{
"highlight": "The mRNA vaccines made by the <em>Pfizer</em> <em>Inc</em>.-BioNTech SE partnership and Moderna Inc. were later found to be more effective at protecting against Covid and have been updated to tackle more recent virus variants.\n\n(With Inputs from Bloomberg)\n\nMilestone Alert!",
"sentiment": 0.7055,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "JNJ",
"name": "Johnson & Johnson",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 73.46099,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Rare but deadly blood clots tied to <em>Johnson</em> & <em>Johnson</em> and AstraZeneca Plc’s Covid-19 vaccines were caused by an autoimmune reaction that some people are predisposed to, researchers have found. This discovery is expected to influence the development of future vaccines, Bloomberg reported.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Rare but deadly blood clots tied to <em>Johnson</em> & <em>Johnson</em> and AstraZeneca Covid-19 vaccines: scientists report to journal",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "M1RN34.SA",
"name": "Moderna, Inc.",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 15.48966,
"sentiment_score": 0.9144,
"highlights": [
{
"highlight": "-BioNTech SE partnership and <em>Moderna</em> <em>Inc</em>. were later found to be more effective at protecting against Covid and have been updated to tackle more recent virus variants.\n\n(With Inputs from Bloomberg)\n\nMilestone Alert! Livemint tops charts as the fastest growing news website in the world 🌏 Click here to know more.\n\nUnlock a world of Benefits!",
"sentiment": 0.9144,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "DJNJ2.BA",
"name": "Johnson & Johnson",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "Healthcare",
"match_score": 73.46564,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Rare but deadly blood clots tied to <em>Johnson</em> & <em>Johnson</em> and AstraZeneca Plc’s Covid-19 vaccines were caused by an autoimmune reaction that some people are predisposed to, researchers have found. This discovery is expected to influence the development of future vaccines, Bloomberg reported.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Rare but deadly blood clots tied to <em>Johnson</em> & <em>Johnson</em> and AstraZeneca Covid-19 vaccines: scientists report to journal",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "DJNJ3.BA",
"name": "Johnson & Johnson",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "Healthcare",
"match_score": 73.46564,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Rare but deadly blood clots tied to <em>Johnson</em> & <em>Johnson</em> and AstraZeneca Plc’s Covid-19 vaccines were caused by an autoimmune reaction that some people are predisposed to, researchers have found. This discovery is expected to influence the development of future vaccines, Bloomberg reported.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Rare but deadly blood clots tied to <em>Johnson</em> & <em>Johnson</em> and AstraZeneca Covid-19 vaccines: scientists report to journal",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "PFED.BA",
"name": "PFIZER INC",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "N/A",
"match_score": 16.537588,
"sentiment_score": 0.7055,
"highlights": [
{
"highlight": "The mRNA vaccines made by the <em>Pfizer</em> <em>Inc</em>.-BioNTech SE partnership and Moderna Inc. were later found to be more effective at protecting against Covid and have been updated to tackle more recent virus variants.\n\n(With Inputs from Bloomberg)\n\nMilestone Alert!",
"sentiment": 0.7055,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "PFECL.SN",
"name": "PFIZER INC",
"exchange": null,
"exchange_long": null,
"country": "cl",
"type": "equity",
"industry": "N/A",
"match_score": 16.537474,
"sentiment_score": 0.7055,
"highlights": [
{
"highlight": "The mRNA vaccines made by the <em>Pfizer</em> <em>Inc</em>.-BioNTech SE partnership and Moderna Inc. were later found to be more effective at protecting against Covid and have been updated to tackle more recent virus variants.\n\n(With Inputs from Bloomberg)\n\nMilestone Alert!",
"sentiment": 0.7055,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "PFE.SN",
"name": "Pfizer Inc.",
"exchange": null,
"exchange_long": null,
"country": "cl",
"type": "equity",
"industry": "Healthcare",
"match_score": 16.537453,
"sentiment_score": 0.7055,
"highlights": [
{
"highlight": "The mRNA vaccines made by the <em>Pfizer</em> <em>Inc</em>.-BioNTech SE partnership and Moderna Inc. were later found to be more effective at protecting against Covid and have been updated to tackle more recent virus variants.\n\n(With Inputs from Bloomberg)\n\nMilestone Alert!",
"sentiment": 0.7055,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "d21343e4-d07b-4425-b940-3f915a0f5a2c",
"title": "Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)",
"description": "– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and...",
"keywords": "Nasdaq:ARVN, Arvinas Inc., Prostate cancer, PROTAC, protein degradation, targeted protein degradation, breast cancer, immuno-oncology, oncology",
"snippet": "– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and sa...",
"url": "https://www.globenewswire.com/news-release/2024/05/16/2883219/0/en/Arvinas-and-Pfizer-Announce-Updated-Clinical-Data-from-Phase-1b-Trial-of-Vepdegestrant-in-Combination-with-Palbociclib-IBRANCE.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/563780a0-f8d9-4e37-8665-b622ef2caa5b",
"language": "en",
"published_at": "2024-05-16T10:00:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "PFECL.SN",
"name": "PFIZER INC",
"exchange": null,
"exchange_long": null,
"country": "cl",
"type": "equity",
"industry": "N/A",
"match_score": 27.25776,
"sentiment_score": 0.182345,
"highlights": [
{
"highlight": "(Nasdaq: ARVN) and <em>Pfizer</em> <em>Inc</em>. (NYSE: PFE) today announced updated clinical data from a Phase 1b combination cohort evaluating vepdegestrant, an investigational oral PROteolysis TArgeting Chimera (PROTAC®) estrogen receptor (ER) degrader, in combination with palbociclib (IBRANCE®).",
"sentiment": -0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "“<em>Pfizer</em> is focused on advancing the next generation of treatment breakthroughs for people with breast cancer,” said Roger Dansey, M.D., Chief Development Officer, Oncology, <em>Pfizer</em>.",
"sentiment": 0.3818,
"highlighted_in": "main_text"
},
{
"highlight": "In July 2021, Arvinas announced a global collaboration with <em>Pfizer</em> for the co-development and co-commercialization of vepdegestrant; Arvinas and <em>Pfizer</em> will share worldwide development costs, commercialization expenses, and profits.\n\nThe U.S.",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Pfizer</em> Oncology\n\nAt <em>Pfizer</em> Oncology, we are at the forefront of a new era in cancer care.",
"sentiment": -0.296,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Pfizer</em>: Breakthroughs That Change Patients’ Lives\n\nAt <em>Pfizer</em>, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.",
"sentiment": 0.5574,
"highlighted_in": "main_text"
},
{
"highlight": "In addition, to learn more, please visit us on www.pfizer.com and follow us on X at @<em>Pfizer</em> and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/<em>Pfizer</em>.",
"sentiment": 0.6204,
"highlighted_in": "main_text"
},
{
"highlight": "Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: Arvinas’ and <em>Pfizer</em> <em>Inc</em>.’s (“<em>Pfizer</em>”) performance of the respective obligations with respect to Arvinas’ collaboration with",
"sentiment": 0.7903,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Pfizer</em>; whether Arvinas and <em>Pfizer</em> will be able to successfully conduct and complete clinical development for vepdegestrant; whether Arvinas and <em>Pfizer</em>, as appropriate, will be able to obtain marketing approval for and commercialize vepdegestrant on current timelines or at all; Arvinas’ ability to protect its intellectual property portfolio; whether",
"sentiment": 0.926,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Pfizer</em> Disclosure Notice:\n\nThe information contained in this release is as of May 16, 2024. <em>Pfizer</em> assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.",
"sentiment": -0.296,
"highlighted_in": "main_text"
},
{
"highlight": "NY: <em>Pfizer</em> <em>Inc</em>: September 2023.\n\n2 Weinberg, RA. pRb and Control of the Cell Cycle Clock. In: Weinberg RA, ed. The Biology of Cancer. 2nd ed. New York, NY: Garland Science; 2014:275-329.\n\n3 Sotillo E, Grana X. Escape from Cellular Quiescence. In: Enders GH, ed. Cell Cycle Deregulation in Cancer. New York, NY: Humana Press; 2010:3-22.",
"sentiment": -0.8442,
"highlighted_in": "main_text"
},
{
"highlight": "Arvinas and <em>Pfizer</em> Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "d201e1ef-ffbe-4450-941e-fd9f73f29081",
"title": "Pfizer Settles Zantac Lawsuits, Agrees To $250M Settlement To Reduce Liability: Report - Pfizer (NYSE:PFE)",
"description": "In a bid to settle thousands of lawsuits over its discontinued heartburn drug Zantac, Pfizer Inc has agreed to pay up to $250 million.",
"keywords": "",
"snippet": "Loading... Loading...\n\nIn a bid to settle thousands of lawsuits over its discontinued heartburn drug Zantac, Pfizer Inc. PFE has agreed to pay up to $250 millio...",
"url": "https://www.benzinga.com/markets/equities/24/05/38865164/pfizer-settles-zantac-lawsuits-agrees-to-250m-settlement-to-reduce-liability-report",
"image_url": "https://cdn.benzinga.com/files/images/story/2024/05/16/Pfizer-shutterstock2.jpeg?width=1200&height=800&fit=crop",
"language": "en",
"published_at": "2024-05-16T07:04:39.000000Z",
"source": "benzinga.com",
"relevance_score": null,
"entities": [
{
"symbol": "PFECL.SN",
"name": "PFIZER INC",
"exchange": null,
"exchange_long": null,
"country": "cl",
"type": "equity",
"industry": "N/A",
"match_score": 43.35766,
"sentiment_score": 0.042967,
"highlights": [
{
"highlight": "In a bid to settle thousands of lawsuits over its discontinued heartburn drug Zantac, <em>Pfizer</em> <em>Inc</em>. PFE has agreed to pay up to $250 million.",
"sentiment": 0.0258,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Pfizer</em>, which sold Zantac between 1998 and 2006, stated that it continues to \"vigorously defend against Zantac lawsuits, which we believe are not supported by reliable science\".",
"sentiment": -0.1232,
"highlighted_in": "main_text"
},
{
"highlight": "\"The company is confident that its Zantac products, which were reviewed and approved by the [US Food and Drug Administration], did not cause cancer when used as directed,\" <em>Pfizer</em> added.\n\nIn March 2024, French pharmaceutical company Sanofi resolved 4,000 cases outside of Delaware, settling all claims against it for an undisclosed sum.",
"sentiment": 0.827,
"highlighted_in": "main_text"
},
{
"highlight": "See Also: Benzinga’s ‘Stock Whisper’ Index: 5 Stocks Investors Secretly Monitor But Don’t Talk About Yet\n\nWhy It Matters: This settlement comes after <em>Pfizer</em> reached an agreement to settle over 10,000 lawsuits about cancer risks associated with Zantac, marking the largest resolution in the litigation.",
"sentiment": -0.6369,
"highlighted_in": "main_text"
},
{
"highlight": "Meanwhile, <em>Pfizer</em> is looking to expand its offerings by introducing a direct-to-consumer medicines platform under the brand “<em>Pfizer</em> for All.” This move aims to provide medical information, mail-order pharmacy, and telehealth services to U.S. patients.",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Pfizer</em> Settles Zantac Lawsuits, Agrees To $250M Settlement To Reduce Liability: Report - <em>Pfizer</em> (NYSE:PFE)",
"sentiment": -0.1531,
"highlighted_in": "title"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "PFECL.SN",
"total_documents": 7,
"sentiment_avg": 0.1966103365023931
}
]
}
Other details
Exchange
- Santiago Stock Exchange
- equity
- N/A
- cl